Hikma Pharmaceuticals’ Post

The healthcare industry is at a critical tipping point. At GE HealthCare, we are focused on delivering on a future of healthcare that will be personalized and preventive, with better patient outcomes at lower costs. Watch the latest episode of Nasdaq and Invesco QQQ’s Innovation Answered series to hear our CFO Jay Saccaro 😊 discuss the role @GEHC is playing in healthcare innovation. #GEHealthCare #FutureofHealthcare #AI #PrecisionCare

The healthcare industry is at a critical tipping point. At GE HealthCare, we are focused on delivering on a future of healthcare that will be personalized and preventive, with better patient outcomes at lower costs. Watch the latest episode of Nasdaq and Invesco QQQ’s Innovation Answered series to hear our CFO Jay Saccaro discuss the role GE HealthCare is playing in healthcare innovation. #GEHealthCare #FutureofHealthcare #AI #PrecisionCare

📈 Is the ASX on the cusp of a biotech boom? Rory Hunter, portfolio manager of SG Hiscock's Medical Technology Fund, thinks so, with some analysts suggesting CSL could get to $500. Read about Rory's outlook here 👉🏻 https://bit.ly/3XmOnaR #sghiscock #fundsmanagement #medicaltechnology #emergingmarkets The above is for information purposes only and does not constitute financial advice. Past performance is not an indication of future performance. We strongly recommend you conduct your own research prior to making investment decisions.

The healthcare industry is at a critical tipping point. At @GE HealthCare, we are focused on delivering on a future of healthcare that will be personalized and preventive, with better patient outcomes at lower costs. Watch the latest episode of @Nasdaq and Invesco QQQ’s Innovation Answered series to hear our CFO @Jay Saccaro discuss the role @GEHC is playing in healthcare innovation. #GEHealthCare #FutureofHealthcare #AI #PrecisionCare

The healthcare industry is at a critical tipping point. At @GE HealthCare, we are focused on delivering on a future of healthcare that will be personalized and preventive, with better patient outcomes at lower costs. Great insights in the latest episode of @Nasdaq and Invesco QQQ’s Innovation Answered series from MedTech Finance Leaders, including our CFO @Jay Saccaro discussing the role @GEHC is playing in healthcare innovation. #GEHealthCare #FutureofHealthcare #AI #PrecisionCare https://lnkd.in/eHURMZmY

“In my experience, everything comes down to product-market fit.” Eric Vest reveals how investors can deal with risk and transcend ‘theories’ to pursue winning business models and strategies: https://bit.ly/3Mwi1Ef #InvestmentWisdom #KeiretsuForumTV #SmartInvesting #InvestorAdvice #InvestmentStrategies

Excited to share that I will be one of only 4 companies presenting at the Keiretsu Forum SoCal Accredited Investor Event today. Keiretsu is the world's largest invitation-only angel investor network with over 3,000 accredited members throughout 64 chapters. Today's event is a regional one with four chapters in attendance. After our successful presentation at the Global Capital Network investor conference last month, Keiretsu approached us. Following two interviews, we are now accepted into the Keiretsu Forum. Impressively, several board members had heard us speak at the same event a year ago and were impressed by our growth and advancements at Oxygen4Life! Join me for my Zoom presentation today from 10AM - NOON where I will be presenting shortly after 11AM. Comment below "link" to get the registration link. You can also request the replay by commenting "link." A big thank you to my entire team and all supporters for helping shape Oxygen4Life. Thank you to my son Alexander Maunu, who without his help, support and putting up with me none of this would have been possible. I love you son! As we prepare for growth and scaling, our focus is on providing technology and solutions for early diagnosis of chronic inflammatory diseases and pain management without drugs or invasive procedures involving radiation. With FDA Cleared Medical Devices, AI-driven non-invasive testing devices, evidence-based patented supplements, and a commitment to sustainability, we offer personalized solutions for managing chronic pain and inflammatory diseases. Our approach aims at improving quality of life and long-term health benefits. #medtech #biotech #wellness #oxygen4life #keiretsu #letsdothis

Last week, Aquestive reported financial results for the second quarter ended June 30, 2024, and provided a business update. The company plans to hold an #epinephrine prodrug technology Investor Day in the coming months – stay tuned for additional details. We are continuing to bring meaningful improvement to patients’ lives through innovative science and delivery technologies. For more information, read our full press release or listen to the replay of the conference call (linked in comments below). #AQST #pharmaceuticalinnovation #investors

Today we announced the successful completion of a $6M private placement for the purchase and sale of an aggregate of 1,237,114 shares of common stock (or pre-funded warrants in lieu thereof) at a purchase price of $4.85 per share (or pre-funded warrants in lieu thereof) and accompanying warrants, priced at-the-market under Nasdaq rules. Each share of common stock (or pre-funded warrant in lieu thereof) is being offered in the offering together with warrants to purchase two share of common stock at an exercise price of $4.60 per share. The warrants will be exercisable immediately upon issuance and expire three years from the date of issuance. The net proceeds from this offering contribute to our efforts in discovering, developing, and deploying promising health innovations, and our commitment to making strides in autoimmunity, health by the numbers, prolonging life through transplantation, population health, and with the successful completion of the recently announced Evofem Biosciences transaction, women’s health. Thank you to H.C. Wainwright & Co., LLC who acted as the exclusive placement agent for this offering. Follow our journey as we continue to break new ground in making promising innovations possible together. https://lnkd.in/dMv_Vp2F #AditxtInnovation #GrowthJourney #InvestorUpdate #NASDAQ_ADTX #Innovations #WomensHealth #Autoimmunity #PopulationHealth #HealthByTheNumbers #ADTX

Only put off until tomorrow what you are willing to die having left undone Becton, Dickinson, and Company Stock Underperforming the Nasdaq: An Opportunity for Savvy Investors! 💪📈 In recent times, Becton, Dickinson, and Company (BDX) have faced challenges in keeping up with the broader market represented by the Nasdaq. However, don't be disheartened, as Wall Street analysts remain optimistic about the company's prospects. 📉💼 Despite its recent underperformance, Becton, Dickinson, and Company, a leading healthcare technology company, have the potential for significant growth in the long run. The company specializes in medical devices and diagnostic systems, offering innovative solutions that improve patient care and advance medical research. 🏥💡 Now is the perfect time for wise investors to take action and seize this opportunity before it's too late! Don't fall prey to the Fear of Missing Out (FOMO). By investing in BDX stock, you can align your financial goals with your commitment to health, wellness, and family. 💰❤️🌱 Health Savings Accounts (HSAs) provide a unique opportunity to grow your wealth while ensuring peace of mind for you and your loved ones. By harnessing the power of investing, you can maximize the earning potential of your HSA funds and secure a brighter financial future. 💪💼🌟 So, dear investor, make the most of this moment. Act now to diversify your investment portfolio, taking advantage of the potential growth in the healthcare industry. Invest in Becton, Dickinson, and Company to not only reap financial rewards but also contribute to the betterment of global healthcare. 📈🌍👨⚕️ #HSA #Investing #Healthcare #Health #Family #Wellness #SeizeTheOpportunity #BrightFinancialFuture 🏥💰🚀